June 24, 2008 -
Melior Discovery, Inc. announced that it has signed an option agreement that provides
Pfizer Inc the exclusive right to negotiate a license to MLR-1023, Melior
’s drug candidate for Type II diabetes. In exchange, Pfizer agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023.
In addition, Melior agreed to utilize its
in-vivo theraTRACE
® indications discovery platform to evaluate the activity of selected Pfizer compounds in partnership with Pfizer...
[PDF] Melior Discovery's Press Release -
June 24, 2008 -Melior Discovery, Inc. announced that it has signed an option agreement that provides Pfizer Inc the exclusive right to negotiate a license to MLR-1023, Melior’s drug candidate for Type II diabetes. In exchange, Pfizer agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023.
In addition, Melior agreed to utilize its in-vivo theraTRACE® indications discovery platform to evaluate the activity of selected Pfizer compounds in partnership with Pfizer... [PDF] Melior Discovery's Press Release -
